In this case study poster presentation, the GPEx® mammalian expression technology was used for the production of Pritumumab and compared to human hybridoma cells.
This poster will demonstrate:
- Master cell bank candidate was developed in 5 months from the start of the project
- GPEx® consistently generated genetically stable higher expressing cell lines
- The GPEx® cell lines demonstrated higher rates ( 20 to 80 fold higher) than the human hybridoma system
- Increased productivity utilizing the GPEX® system to move projects into clinical trials faster